TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Date: 14-08-2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai — 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Submission of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter ended on 30th June, 2025.

Please find the enclosed herewith Unaudited Financial Results (Standalone & Consolidated) for the Quarter ended on 30TH June 2025 along with Limited Review Report thereon approved by the Board of Directors of the Company at its Meeting held on Thursday, **14th August, 2025 at Shop No 1 Building Name: Shivprasad Harihar Singh Compound, Block Sector: Jogeshwari East, Road: Caves Road. Pratap Nagar -Mumbai, Maharashtra, 400060 at 3.00 pm**, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and record.

Thanking you.

For Tejnaksh Healthcare Limited

Rawandale

Dr. Ashish V. Rawandale
Managing Director
DIN: - 02005733

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEINAKSH HEALTHCARE LIMITED
STATEMENT OF STANDALONE FINANCIAL RESULTS FOR QUARTER ENDED June 30, 2025
CIN : L85100MH2008PLC179034

(₹ in lakhs, except per share data)

Particulars	Quarter Ended			Year Ended
	Jun-25 Unaudited	Mar-25 Audited	Jun-24 Unaudited	Mar-25 Audited
REVENUE				
Revenue from operations (net)	178.06	240.43	217.55	879.78
Other income	8.43	6.23	6.90	35.26
Total income	**186.48**	**246.66**	**224.45**	**915.04**
EXPENSES				
Cost of materials consumed	0.07	0.09	1.10	0.23
Purchases of stock-in-trade	11.89	13.88	15.96	57.18
Changes in inventories of finished goods, work-in-progress & stock-in-trade	(5.40)	6.82	4.48	7.51
Employee benefits expense	18.47	21.67	19.88	76.91
Finance costs	4.33	4.02	11.76	37.60
Depreciation and amortization expense	32.81	15.01	20.00	78.84
Other expenses	79.24	81.59	73.02	290.38
Total expenses	**141.41**	**143.08**	**146.20**	**548.65**
Profit before exceptional items & tax	**45.07**	**103.58**	**78.25**	**366.39**
Tax expense:				
Current tax	7.51	21.13	15.82	83.34
Deferred tax	3.84	7.09	3.88	20.90
Total tax expenses	**11.35**	**28.23**	**19.69**	**104.24**
Profit /(Loss) for the period/year	**33.73**	**75.35**	**58.56**	**262.15**
Other comprehensive income not to be reclassified to profit and loss :				
Remeasurement of defined employee benefit plans	0.34	(0.49)	0.62	1.37
Income tax credit (expense) relating to above items	(0.09)	0.13	(0.16)	(0.34)
Total other comprehensive income for the period, net of tax	**0.25**	**(0.36)**	**0.46**	**1.03**
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	**33.98**	**74.99**	**59.02**	**263.18**
Paid up equity share capital (Face value Rs 5/- each.)	1,015.68	1,015.68	1,015.68	1015.68
Reserves and surplus during previous year				1525.16
Basic and diluted earnings per share (INR)	0.17	0.37	0.29	1.29

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Unaudited Standalone Financial Results for the quarter ended June 30, 2025

1. The above unaudited Standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2025. The Statutory Auditors of the Company have carried out a limited review of the Standalone unaudited financial results for the quarter and three months ended on June 30, 2025. Their limited review report does not have any modification.

2. The above unaudited Standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. Figures for the three months ended March 31, 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year

4. As the company operates in Single Segment only i.e. Medical and Healthcare Services, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

5. Figures for the previous year/periods have been regrouped and reclassified to confirm the classification of the current year/period, where necessary.

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: August 14, 2025
Place: Mumbai

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the Quarter ended June 30, 2025 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to,
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Company') for the quarter ended June 30, 2025 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations)

2. This Statement which is the responsibility of the Company's Management and has been approved by the Company's Bsoard of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended March 31, 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W



Vikas Asawa
Partner
Membership No.: 172133
UDIN: 25172133BMIAEO2336

Place: Mumbai
Date: August 14, 2025

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

TEJNAKSH HEALTHCARE LIMITED
STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2025
CIN : L85100MH2008PLC179034

(₹ in lakhs, except per share data)

Particulars	Quarter Ended			Year Ended
	Jun-25 Unaudited	Mar-25 Audited	Jun-24 Unaudited	Mar-25 Audited
REVENUE				
Revenue from operations (net)	263.97	321.48	312.39	1,289.71
Other income	9.42	7.21	7.22	40.43
Total income	**273.39**	**328.69**	**319.60**	**1,330.14**
EXPENSES				
Cost of materials consumed	0.07	0.09	1.10	0.23
Purchases of stock-in-trade	25.14	29.27	31.16	124.58
Changes in inventories of finished goods, work-in-progress & stock-in-trade	1.49	9.34	2.90	3.86
Employee benefits expense	33.46	39.07	34.84	152.63
Finance costs	5.34	1.00	11.77	37.62
Depreciation and amortization expense	35.67	17.45	22.80	90.99
Other expenses	143.72	172.99	135.02	601.09
Total expenses	**244.89**	**269.20**	**239.60**	**1,011.00**
Profit/(Loss) before exceptional items & tax	**28.50**	**59.48**	**80.00**	**319.14**
Exceptional items	-	-	-	-
Profit/(Loss) before tax	**28.50**	**59.48**	**80.00**	**319.14**
Tax expense				
Current tax	7.51	21.10	15.82	85.10
Deferred tax	(0.28)	(3.95)	4.32	10.99
Total tax expense	**7.23**	**17.15**	**20.14**	**96.09**
Profit/(Loss) for the period/year	**21.27**	**42.33**	**59.87**	**223.05**
Items not be reclassified to profit or loss :				
Remeasurement of defined employee benefit plans	0.63	2.53	0.78	2.53
Income tax credit(expense) relating to above items	(0.16)	(2.98)	(0.20)	(0.64)
Other comprehensive income/(loss) for the period, net of tax	**0.47**	**(0.45)**	**0.58**	**1.89**
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	**21.74**	**41.88**	**60.45**	**224.94**
Profit/(Loss) for the year attributable to:				
Equity holders of the parent	25.04	50.83	59.54	232.78
Non-controlling Interests	(3.77)	8.50	0.33	(9.73)
Other comprehensive income/(loss) for the year attributable to:				
Equity holders of the parent	0.42	0.06	0.55	1.67
Non-controlling Interests	0.05	(0.51)	0.03	0.22

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Total comprehensive income/(loss) for the year attributable to:				
Equity holders of the parent	25.93	50.89	60.09	234.45
Non-controlling interests	(4.19)	(9.01)	0.36	(9.51)
Paid Up equity share capital (face value 5/- each)	1,015.68	1,015.68	1,015.68	1,015.68
Reserves and surplus during the previous year				1,575.40
Earnings per share (EPS)				
Basic and diluted earing per share	0.12	0.21	0.29	1.15
	Not Annualized			

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Office : Shop No. 1, Shivprasad Harihar Singh Compound, Jogeshwari East, Caves Road, Pratap Nagar, Mumbai, Maharashtra - 400060
Head Office : Institute of Urology Sakri Raod, Dhule - 424001
CIN : L85100MH2008PLC179034, **E-mail :** Instituteofurology@gmail.com
Website : www.tejnaksh.com | **Tel. No.** 022-27454 2311, 02562 - 245322 / 245995

Notes to the Unaudited Consolidated Financial Results for the quarter June 30, 2025

1. The above unaudited Consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 14, 2025. The Statutory Auditors of the Company have carried out a limited review of the Consolidated unaudited financial results for quarter ended June 30, 2025. Their limited review report does not have any modification.

2. The above unaudited Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended.

3. The figures for the three months ended March 31, 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year.

4. As the Group operates in Single Segment only i.e. Medical and Healthcare Services, it did not give rise to different operating segments in accordance with Ind AS 108 - Operating Segments.

5. Figures for the previous year/periods have been regrouped and reclassified to confirm the classification of the current year/period, where necessary.

Tejnaksh Healthcare Limited MUMBAI

For and behalf of Board of Directors of
Tejnaksh Healthcare Limited

Dr. A. V. Rawandale
Managing Director
DIN: 02005733

Date: August 14, 2025
Place: Mumbai

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Tejnaksh Healthcare Limited for the quarter ended June 30, 2025 pursuant to the Regulation 33 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Tejnaksh Healthcare Limited** ('hereinafter referred to as 'the Parent') and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2025 (the 'Statement'), attached herewith, being submitted by the Parent pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Regulations).

2. This Statement which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act') as amended, read with relevant rules issued thereunder ('Ind AS 34') and other recognized accounting principles generally accepted in India and is in compliance with the regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes the results of the following entities:
   a. Holding Company: Tejnaksh Healthcare Limited
   b. Subsidiary: Tej Vedaant Healthcare Private Limited

5. Attention is drawn to the fact that the figures for the three months ended March 31, 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit

6. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.
Chartered Accountants
Firm's Registration No.: 105834W

MAHESHWARI & CO. FRN 105834W MUMBAI Chartered Accountants

Vikas Asawa
(Partner)
Membership No.: 172133

Place: Mumbai
Date: August 14, 2025

UDIN: 25172133BMIAEP3130